65 CHF CHF 65.00
AG-CR1-3611-M02525 mgCHF 65.00
AG-CR1-3611-M100100 mgCHF 110.00
|Synonyms||1-Thio-β-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetra- acetate; NSC 321521; SKF 39162; Triethylphosphine gold|
|Merck Index||14: 878|
|Appearance||White to off-white solid.|
|Solubility||Soluble in DMSO or 100% ethanol. Insoluble in water.|
|Identity||Determined by 1H-NMR.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Protect from light.|
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
- Anti-inflammatory and anti-arthritic agent. Represses the activation of the NLRP3/IL-1β pathway.
- Inhibitor of 5-lipoxygenase in human neutrophils, IKB kinase (IKK) by modifying Cys-179 of the IKKβ subunit 5.
- Potent thioredoxin reductase (TrxR) inhibitor. Induces mitochondrial membrane permeability transition.
- Anti-cancer compound with anti-proliferative activity. Shown to induce apoptosis and necrosis.
- STAT3 and telomerase activity inhibitor.
- Proteasomal deubiquitinase inhibitor.
- Antibiotic, antiviral and antiparasitic compound.
- Auranofin. New oral gold compound for treatment of rheumatoid arthritis: A.E. Finkelstein, et al.; Ann. Rheum. Dis. 35, 251 (1976)
- Inhibition of alveolar macrophage 5-lipoxygenase metabolism by auranofin: M. Peters-Golden & C. Shelly; Biochem. Pharmacol. 38, 1589 (1989)
- Gold compound auranofin inhibits IkappaB kinase (IKK) by modifying Cys-179 of IKKbeta subunit: K.I. Jeon, et al.; Exp. Mol. Med. 35, 61 (2003)
- Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells: C. Marzano, et al.; Free Radic. Biol. Med. 42, 872 (2007)
- Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells: S. Han, et al.; Arch. Pharm. Res. 31, 370 (2008)
- The gold compound auranofin induces apoptosis of human multiple myeloma cells through both down-regulation of STAT3 and inhibition of NF-κB activity: A. Nakaya, et al.; Leuk. Res. 35, 243 (2011)
- The biological activity of auranofin: implications for novel treatment of diseases: J.M. Madeira, et al.; Inflammopharmacology 20, 297 (2012) (Review)
- Antiproliferative effect of gold(I) compound auranofin through inhibition of STAT3 and telomerase activity in MDA-MB 231 human breast cancer cells: N.H. Kim, et al.; BMB Rep. 46, 59 (2013)
- Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections: M.I. Cassetta, et al.; Biometals 27, 787 (2014)
- Suppression of the pro-inflammatory NLRP3/interleukin-1β pathway in macrophages by the thioredoxin reductase inhibitor auranofin: E. Isakov, et al.; Biochim. Biophys. Acta 1840, 3153 (2014)
- Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth: M. Liu, et al.; Oncotarget 5, 5453 (2014)
- Auranofin induces apoptosis and necrosis in HeLa cells via oxidative stress and glutathione depletion: B.R. You, et al.; Mol. Med. Rep. 11, 1428 (2015)
- Auranofin: repurposing an old drug for a golden new age: C. Roder & M.J. Thomson; Drugs R.D. 15, 13 (2015) (Review)
- Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis: M.B. Harbut, et al.; PNAS 112, 4453 (2015)